MBX
MBX Biosciences, Inc. Common StockNASDAQHealthcare$32.99+2.17%ClosedMarket Cap: $1.11B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.26
P/S
0.00
EV/EBITDA
-10.82
DCF Value
$2.02
FCF Yield
-7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-28.7%
ROA
-22.6%
ROIC
-26.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-25.8M | $-22.1M | $-0.49 | — |
| FY 2025 | $0.00 | -Infinity% | $-98.1M | $-87.0M | $-2.38 | — |
| Q3 2025 | $0.00 | -Infinity% | $-23.9M | $-21.6M | $-0.63 | — |
| Q2 2025 | $0.00 | NaN% | $-21.8M | $-19.4M | $-0.58 | — |
| Q1 2025 | $0.00 | NaN% | $-26.5M | $-23.9M | $-0.71 | — |
| Q4 2024 | $0.00 | NaN% | $-18.6M | $-15.6M | $-0.47 | — |
| FY 2024 | $0.00 | NaN% | $-68.2M | $-61.9M | $-1.85 | — |
| Q3 2024 | $0.00 | NaN% | $-19.6M | $-18.1M | $-0.54 | — |
| Q2 2024 | $0.00 | NaN% | $-16.7M | $-15.9M | $-0.48 | — |
| Q1 2024 | $0.00 | NaN% | $-13.3M | $-12.3M | $-0.37 | — |
| Q4 2023 | $0.00 | NaN% | $-10.0M | $-8.8M | $-0.28 | — |
| FY 2023 | $0.00 | NaN% | $-35.3M | $-32.6M | $-1.02 | — |